Chiropractors in Dillingham, AK Accepting Medicare
2 Chiropractors found. Showing 1 - 2
 Arctic Chiropractic Dillingham Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 222 Main St, Dillingham, AK 99576 Phone: 907-842-2300 |
 Chance Jeffrey Charlton, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 222 Main Street, Box 1227, Dillingham, AK 99576 Phone: 907-842-2300 Fax: 907-842-2303 |
News Archive
Rice chemists synthesize new, improved contrast agents for real-time tracking of stem cells in the body
Rice University researchers have synthesized a new and greatly improved generation of contrast agents for tagging and real-time tracking of stem cells in the body.
UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells
UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
New molecule effective against lice
French medical researchers from the AP-HP (Henri Mondor Hospital and Avicenne Hospital) and Inserm (Unit 738 "Models and methods for therapeutic evaluation of chronic illnesses" and CIC 202, at Tours) have recently demonstrated the effectiveness of a new molecule in the fight against lice. Faced with the emergence of increasing resistance to conventional treatments by these parasites, this new medication represents a real therapeutic alternative which is effective in 95% of cases.
Novel HIV prevention products for women demonstrate safety in clinical studies
Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.
Molecular Partners closes its CHF 46 million Series B equity investment round
Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).
› Verified 1 days ago